JP2003518064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003518064A5 JP2003518064A5 JP2001546648A JP2001546648A JP2003518064A5 JP 2003518064 A5 JP2003518064 A5 JP 2003518064A5 JP 2001546648 A JP2001546648 A JP 2001546648A JP 2001546648 A JP2001546648 A JP 2001546648A JP 2003518064 A5 JP2003518064 A5 JP 2003518064A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- substituted
- chemical
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 34
- 239000000126 substance Substances 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 8
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 206010019196 Head injury Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- HDCXQTPVTAIPNZ-UHFFFAOYSA-N n-({[4-(aminosulfonyl)phenyl]amino}carbonyl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=C(S(N)(=O)=O)C=C1 HDCXQTPVTAIPNZ-UHFFFAOYSA-N 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000008061 calcium-channel-blocking effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical class C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
Images
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17283199P | 1999-12-20 | 1999-12-20 | |
| US60/172,831 | 1999-12-20 | ||
| US09/476,927 US6387897B1 (en) | 1998-06-30 | 1999-12-30 | Preferentially substituted calcium channel blockers |
| US09/476,927 | 1999-12-30 | ||
| PCT/CA2000/001557 WO2001045709A1 (en) | 1999-12-20 | 2000-12-20 | Substituted piperazine and piperidine calcium channel blockers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003518064A JP2003518064A (ja) | 2003-06-03 |
| JP2003518064A5 true JP2003518064A5 (enExample) | 2009-08-27 |
Family
ID=26868504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001546648A Pending JP2003518064A (ja) | 1999-12-20 | 2000-12-20 | 置換ピペラジンおよびピペリジンカルシウムチャネルブロッカー |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6387897B1 (enExample) |
| EP (1) | EP1244451B1 (enExample) |
| JP (1) | JP2003518064A (enExample) |
| KR (1) | KR100823889B1 (enExample) |
| CN (1) | CN100477992C (enExample) |
| AT (1) | ATE333878T1 (enExample) |
| AU (1) | AU784206B2 (enExample) |
| BR (1) | BR0016530A (enExample) |
| CA (1) | CA2394327C (enExample) |
| DE (1) | DE60029634T2 (enExample) |
| DK (1) | DK1244451T3 (enExample) |
| ES (1) | ES2269220T3 (enExample) |
| HK (1) | HK1049969B (enExample) |
| IL (1) | IL150117A0 (enExample) |
| MX (1) | MXPA02006138A (enExample) |
| NO (1) | NO323724B1 (enExample) |
| PT (1) | PT1244451E (enExample) |
| WO (1) | WO2001045709A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040259866A1 (en) * | 1998-06-30 | 2004-12-23 | Snutch Terrance P. | Calcium channel blockers comprising two benzhydril moieties |
| US6943168B2 (en) * | 1998-06-30 | 2005-09-13 | Neuromed Technologies Inc. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
| US20060084660A1 (en) * | 1998-06-30 | 2006-04-20 | Neuromed Technologies Inc. | Calcium channel blockers comprising two benzhydril moieties |
| WO2004089922A2 (en) * | 1998-06-30 | 2004-10-21 | Neuromed Technologies, Inc. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
| US20040266784A1 (en) * | 1998-06-30 | 2004-12-30 | Snutch Terrance P. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
| US6387897B1 (en) * | 1998-06-30 | 2002-05-14 | Neuromed Technologies, Inc. | Preferentially substituted calcium channel blockers |
| US6951862B2 (en) * | 1998-06-30 | 2005-10-04 | Neuromed Technologies, Inc. | Calcium channel blockers comprising two benzhydril moieties |
| US7186726B2 (en) * | 1998-06-30 | 2007-03-06 | Neuromed Pharmaceuticals Ltd. | Preferentially substituted calcium channel blockers |
| US7151102B2 (en) * | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2003066040A1 (en) | 2002-02-05 | 2003-08-14 | Ajinomoto Co.,Inc. | Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist |
| US20030199523A1 (en) * | 2002-02-28 | 2003-10-23 | Snutch Terrance P. | Heterocyclic calcium in channel blockers |
| US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| JP2006522742A (ja) * | 2003-04-08 | 2006-10-05 | ニューロームド テクノロジーズ、インク. | ピペラジンから距離をおいて配置したベンズヒドリル基から成る一群のカルシウムチャンネル阻害剤 |
| WO2004093813A2 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders |
| WO2004093816A2 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent |
| EP1633343A1 (en) * | 2003-05-30 | 2006-03-15 | Neuromed Technologies, Inc. | 3-aminomethyl-pyrrolidines as n-type calcium channel blockers |
| WO2005015159A2 (en) * | 2003-08-08 | 2005-02-17 | The Regents Of The University Of California. | Methods for modulating a drug-related effect or behavior |
| US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
| US7507760B2 (en) * | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
| AU2005231872A1 (en) * | 2004-04-09 | 2005-10-20 | Neuromed Pharmaceuticals Ltd. | Diarylamine derivatives as calcium channel blockers |
| US20050227999A1 (en) * | 2004-04-09 | 2005-10-13 | Neuromed Technologies Inc. | Diarylamine derivatives as calcium channel blockers |
| GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| KR20070063526A (ko) | 2004-08-30 | 2007-06-19 | 뉴로메드 파머큐티칼즈 리미티드 | 칼슘 채널 차단제인 우레아 유도체 |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| US7511077B2 (en) | 2005-02-09 | 2009-03-31 | Neuromed Pharmaceuticals Ltd. | Diamine calcium channel blockers |
| JP2008534630A (ja) * | 2005-04-08 | 2008-08-28 | ニューロメッド ファーマシューティカルズ リミテッド | 疼痛の軽減のためのn型カルシウムチャネルブロッカーを含む組み合わせ治療の方法 |
| WO2007018459A1 (en) * | 2005-08-08 | 2007-02-15 | Astrazeneca Ab | Therapeutic agents |
| US8022177B2 (en) * | 2005-09-30 | 2011-09-20 | The Board Of Trustees Of The University Of Illinois | Peptides and calcium regulation in mammalian cells |
| US8299211B2 (en) * | 2005-09-30 | 2012-10-30 | The Board Of Trustees Of The University Of Illinois | Peptides and regulation of calcium channels |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| US8791264B2 (en) * | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) * | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| CA2651811A1 (en) * | 2006-05-11 | 2007-11-22 | Neuromed Pharmaceuticals Ltd. | Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
| WO2008031227A1 (en) * | 2006-09-14 | 2008-03-20 | Neuromed Pharmaceuticals Ltd. | Diaryl piperidine compounds as calcium channel blockers |
| US20100105682A1 (en) * | 2006-10-13 | 2010-04-29 | Hassan Pajouhesh | Cyclopropyl-piperazine compounds as calcium channel blockers |
| TWI404716B (zh) * | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮(phthalazinone)衍生物 |
| WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| ES2428326T3 (es) * | 2007-10-04 | 2013-11-07 | Merck Sharp & Dohme Corp. | Derivados de aril sulfona sustituida como bloqueadores de canales de calcio |
| KR101598231B1 (ko) * | 2007-10-17 | 2016-02-26 | 쿠도스 파마슈티칼스 리미티드 | 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2h-프탈라진-1-온 |
| WO2009132454A1 (en) * | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Di-t-butylphenyl piperazines as calcium channel blockers |
| EP2344450A1 (en) * | 2008-09-29 | 2011-07-20 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
| CA2737400C (en) * | 2008-10-07 | 2016-11-22 | Astrazeneca Uk Limited | Pharmaceutical formulation 514 |
| EP2352501B1 (en) * | 2008-11-03 | 2014-01-01 | ChemoCentryx, Inc. | Compounds for use in the treatment of osteoporosis |
| WO2011026240A1 (en) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| AU2011305610A1 (en) | 2010-09-20 | 2013-03-14 | Kareus Therapeutics, Sa | Methods and compositions for treatment of diabetes and dyslipidemia |
| US8409560B2 (en) | 2011-03-08 | 2013-04-02 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| US8591944B2 (en) | 2011-03-08 | 2013-11-26 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| EP2961403A4 (en) | 2013-03-01 | 2016-11-30 | Zalicus Pharmaceuticals Ltd | HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL |
| US10168144B2 (en) | 2016-03-25 | 2019-01-01 | Sony Corporation | Optical apparatus for 3D data collection |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1051527A (enExample) | 1964-07-31 | |||
| US3997539A (en) | 1974-05-31 | 1976-12-14 | American Hoechst Corporation | 3-(4-Acylaminopiperazin-1-yl alkyl)indoles, precursors and processes for the preparation thereof |
| US4188485A (en) | 1978-06-16 | 1980-02-12 | G. D. Searle & Co. | 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds |
| JPS61155358A (ja) | 1984-12-21 | 1986-07-15 | Suntory Ltd | ジアリール酪酸誘導体 |
| FR2584723B1 (fr) | 1985-07-09 | 1988-02-12 | Adir | Nouveaux derives du dihydro-2,3 benzofuranne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| DE3600390A1 (de) | 1986-01-09 | 1987-07-16 | Hoechst Ag | Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel |
| US5386025A (en) | 1990-02-20 | 1995-01-31 | The Salk Institute Biotechnology/Industrial Associates | Calcium channel compositions and methods |
| IE73232B1 (en) | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| US5703071A (en) | 1990-08-29 | 1997-12-30 | Pharmacia & Upjohn Company | Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases |
| DE4111861A1 (de) | 1991-04-11 | 1992-10-15 | Schwabe Willmar Gmbh & Co | Benzopyranone, verfahren zu ihrer herstellung und verwendung |
| KR950704284A (ko) | 1992-12-22 | 1995-11-17 | 데이비드 로버츠 | 칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists) |
| BR9406080A (pt) | 1993-12-08 | 1996-02-06 | Alcon Lab Inc | Compostos que tem tanto antividade de anaonista potente de calcio como de antioxidante e uso dos mesmos como agentes citoprotetores |
| US5623051A (en) | 1994-11-10 | 1997-04-22 | University Of Washington | Methods and compositions for screening for presynaptic calcium channel blockers |
| CA2304503A1 (en) | 1997-09-23 | 1999-04-01 | Graham Johnson | Selective cpla2 inhibitors |
| ID24475A (id) | 1997-11-18 | 2000-07-20 | Teijin Limeted Cs | Turunan-turunan amina siklik dan penggunaannya sebagai obat |
| US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
| US6387897B1 (en) * | 1998-06-30 | 2002-05-14 | Neuromed Technologies, Inc. | Preferentially substituted calcium channel blockers |
| US6268377B1 (en) | 1998-09-28 | 2001-07-31 | Merck & Co., Inc. | Method for treating androgen-related conditions |
| US6267945B1 (en) | 1998-12-18 | 2001-07-31 | Neuromed Technologies, Inc. | Farnesol-related calcium channel blockers |
-
1999
- 1999-12-30 US US09/476,927 patent/US6387897B1/en not_active Expired - Lifetime
-
2000
- 2000-12-20 ES ES00988531T patent/ES2269220T3/es not_active Expired - Lifetime
- 2000-12-20 KR KR1020027007951A patent/KR100823889B1/ko not_active Expired - Fee Related
- 2000-12-20 MX MXPA02006138A patent/MXPA02006138A/es active IP Right Grant
- 2000-12-20 JP JP2001546648A patent/JP2003518064A/ja active Pending
- 2000-12-20 CN CNB008174369A patent/CN100477992C/zh not_active Expired - Fee Related
- 2000-12-20 AT AT00988531T patent/ATE333878T1/de active
- 2000-12-20 WO PCT/CA2000/001557 patent/WO2001045709A1/en not_active Ceased
- 2000-12-20 DE DE60029634T patent/DE60029634T2/de not_active Expired - Lifetime
- 2000-12-20 EP EP00988531A patent/EP1244451B1/en not_active Expired - Lifetime
- 2000-12-20 PT PT00988531T patent/PT1244451E/pt unknown
- 2000-12-20 IL IL15011700A patent/IL150117A0/xx active IP Right Grant
- 2000-12-20 DK DK00988531T patent/DK1244451T3/da active
- 2000-12-20 CA CA2394327A patent/CA2394327C/en not_active Expired - Fee Related
- 2000-12-20 AU AU24956/01A patent/AU784206B2/en not_active Ceased
- 2000-12-20 BR BR0016530-1A patent/BR0016530A/pt not_active Application Discontinuation
- 2000-12-20 HK HK03102253.5A patent/HK1049969B/en not_active IP Right Cessation
-
2002
- 2002-01-29 US US10/060,900 patent/US6617322B2/en not_active Expired - Fee Related
- 2002-06-19 NO NO20022947A patent/NO323724B1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003518064A5 (enExample) | ||
| PL1663197T3 (pl) | Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy | |
| US6387897B1 (en) | Preferentially substituted calcium channel blockers | |
| CA2206776C (en) | N-sulfonylindoline derivatives carrying an amide functional group, their preparation and the pharmaceutical compositions in which they are present | |
| US7064128B2 (en) | Preferentially substituted calcium channel blockers | |
| CA2429844A1 (en) | Mch antagonists and their use in the treatment of obesity | |
| BRPI0412219A (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença | |
| SE0104332D0 (sv) | Therapeutic agents | |
| NO20024042D0 (no) | Aryl-fusjonerte azapolysykliske forbindelser | |
| MXPA06002296A (es) | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. | |
| JP2004520302A5 (enExample) | ||
| DE60120138T8 (de) | Amid-verbindungen und deren verwendung | |
| RU2010137115A (ru) | Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов | |
| ATE512961T1 (de) | Amorphes nebivolol hydrochlorid und seine herstellung | |
| JP2004529953A5 (enExample) | ||
| JP2005517665A5 (enExample) | ||
| CA2406266A1 (en) | A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds | |
| EP0233762B1 (en) | Use of aromatic diamines for the treatment of angina pectoris, and diamines therefor | |
| JP5443372B2 (ja) | 神経因性疼痛に活性な薬物 | |
| HUT57740A (en) | Process for producing n-arylpiperazine alkaneamide derivatives of general formula (i) and pharmaceutical compositions promoting sleep and comprising such compounds | |
| EP1253139A3 (en) | Multioligoanilinated fullerenes | |
| WO2024226819A3 (en) | Ibogaine and noribogaine analogs and methods of use | |
| JP2005506324A5 (enExample) | ||
| JP3038018B2 (ja) | 新規n―アミノアルキル―2―アントラセンカルボキサミド;新規ドーパミン受容体サブタイプ特異的リガンド | |
| HU195644B (en) | Process for producing new phenyl-acetonitril derivatives and pharmaceutical compositions containing them as active components |